FIELD: medicine; hematology.
SUBSTANCE: invention relates to medicine, namely to hematology; it can be used for the treatment of Willebrand disease type 2 or type 3. A lyophilized composition of a recombinant von Willebrand factor (hereinafter – rVWF) is proposed, containing rVWF, where rVWF is a composition of highly molecular VWF multimers, containing at least 40% of VWF decamers or higher-order multimers, buffer, trehalose, mannitol, glycine, and polysorbate 80.
EFFECT: lyophilized rVWF composition provides stabilization of rVWF due to binding of at least one FVIII molecule.
10 cl, 22 dwg, 36 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF BLOOD-CLOTTING DISORDER THROUGH INTRODUCTION OF RECOMBINANT WF | 2012 |
|
RU2680402C2 |
| TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT vWF | 2012 |
|
RU2628537C2 |
| CONJUGATES OF BLOOD COAGULATION PROTEINS | 2010 |
|
RU2595442C2 |
| TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING PLANNED SURGICAL INTERVENTION BY ADMINISTRATION OF RECOMBINANT VWF | 2018 |
|
RU2766118C2 |
| BLOOD COAGULATION PROTEIN CONJUGATES | 2010 |
|
RU2744370C2 |
| OXICODON AND NALOXON-CONTAINING PHARMACEUTICAL COMPOSITIONS WITH INSTANT RELEASE | 2010 |
|
RU2522212C2 |
| METHOD OF PREPARING THE STANDARDIZED CONCENTRATION OF HUMAN VILLEBRAND FACTOR AND CONCENTRATE OBTAINED BY THIS METHOD | 1992 |
|
RU2088590C1 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
| CONJUGATED FACTOR VIII MOLECULES | 2009 |
|
RU2573587C2 |
| PRODUCING PEGYLATED FRAGMENTS OF GD2-SPECIFIC ANTIBODIES INDUCING DIRECT CELL DEATH OF GD2-POSITIVE TUMOR CELLS, AND USE THEREOF IN THERAPY OF GD2-POSITIVE TUMORS | 2017 |
|
RU2663104C1 |
